Alpha Tau Medical Ltd. has announced significant interim results from its ongoing clinical trial for the treatment of recurrent glioblastoma, a particularly aggressive form of brain cancer. The results indicate that all eight patients treated with the Alpha DaRT therapy are alive, with a median follow-up of 6.9 months. This development is crucial as glioblastoma patients typically face a grim prognosis, with average survival rates around eight months.

The announcement was made on November 15, 2026, and detailed in a filing with the SEC on November 16, 2026. The positive outcomes from the trial could position Alpha Tau as a leader in the surgical and medical instruments and apparatus industry, particularly in the oncology sector.

Background

Alpha Tau Medical Ltd., incorporated in Israel, specializes in developing innovative cancer therapies. The company operates under the SIC code 3841, which pertains to surgical and medical instruments and apparatus. Alpha Tau is publicly traded on Nasdaq under the tickers DRTS and DRTSW. The firm aims to revolutionize cancer treatment through its unique Alpha DaRT technology, which utilizes alpha radiation to target tumors.

What the Filing Says

The SEC filing, which includes a press release, highlights the interim results from the U.S. REGAIN trial, stating, "All patients treated are alive with median survival not reached, 6.9 months median follow-up in the first six evaluable patients with 100% ORR, 100% feasibility and no unanticipated serious adverse events." This indicates a strong safety profile for the treatment.

Impact

These results are likely to affect not only the patients involved but also the broader medical community and industry stakeholders. With glioblastoma being one of the most challenging cancers to treat, the success of Alpha Tau's trial could lead to increased interest and investment in similar therapies. Additionally, competitors in the surgical and medical instruments space may need to reevaluate their product offerings in light of Alpha Tau's promising results.

What's Next

The filing does not specify what happens next, but a conference call was scheduled for November 16, 2026, at 8:30 am ET to discuss the trial results further. This call will likely provide additional insights into the company's plans for future trials and potential market submissions.